These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 27070364)

  • 21. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
    Pawate S; Wang L; Song Y; Sriram S
    J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
    J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
    Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing response to interferon-β in a multicenter dataset of patients with MS.
    Sormani MP; Gasperini C; Romeo M; Rio J; Calabrese M; Cocco E; Enzingher C; Fazekas F; Filippi M; Gallo A; Kappos L; Marrosu MG; Martinelli V; Prosperini L; Rocca MA; Rovira A; Sprenger T; Stromillo ML; Tedeschi G; Tintorè M; Tortorella C; Trojano M; Montalban X; Pozzilli C; Comi G; De Stefano N;
    Neurology; 2016 Jul; 87(2):134-40. PubMed ID: 27306626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.
    Abolfazli R; Hosseini A; Gholami Kh; Javadi MR; Torkamandi H; Emami S
    ISRN Neurol; 2012; 2012():786526. PubMed ID: 22928117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological and nonbiological complex drugs for multiple sclerosis in Latin America: regulations and risk management.
    Carrá A; Macías Islas MA; Tarulla A; Bichuetti DB; Finkelsztejn A; Fragoso YD; Árcega-Revilla R; Cárcamo Rodríguez C; Durán JC; Bonitto JG; León R; Oehninger Gatti C; Orozco G; Vizcarra Escobar D
    Expert Rev Neurother; 2015 Jun; 15(6):597-600. PubMed ID: 25924772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
    Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.
    Bonavita S; Dinacci D; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Bresciamorra V; Orefice G; Paciello M; Coniglio G; Di Costanzo A; Valentino P; Patti F; Salemi G; Simone I; Tedeschi G
    Neurol Sci; 2006 Sep; 27 Suppl 5():S365-8. PubMed ID: 16998722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
    Patti F; Reggio E; Palermo F; Fiorilla T; Politi G; Nicoletti A; Reggio A
    J Neurol; 2004 Dec; 251(12):1502-6. PubMed ID: 15645351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability.
    Jelinek GA; Weiland TJ; Hadgkiss EJ; Marck CH; Pereira N; van der Meer DM
    Neurol Res; 2015 Aug; 37(8):662-73. PubMed ID: 25905471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.
    Shirani A; Zhao Y; Karim ME; Petkau J; Gustafson P; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
    Eur J Neurol; 2014 Jun; 21(6):835-44. PubMed ID: 24351059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta-interferon for multiple sclerosis.
    Rudick RA; Goelz SE
    Exp Cell Res; 2011 May; 317(9):1301-11. PubMed ID: 21396360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.